Viking Therapeutics, Inc. (LON:0VQA)
London
· Delayed Price · Currency is GBP · Price in USD 25.37
-0.82 (-3.14%)
At close: Apr 24, 2025
Viking Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Cash & Equivalents | 37.94 | 26.68 | 55.52 | 36.63 | 26.37 | 29.12 | Upgrade
|
| Short-Term Investments | 813.92 | 875.94 | 306.56 | 118.85 | 175.73 | 219.27 | Upgrade
|
| Cash & Short-Term Investments | 851.86 | 902.61 | 362.08 | 155.49 | 202.1 | 248.39 | Upgrade
|
| Cash Growth | -11.54% | 149.29% | 132.87% | -23.07% | -18.63% | -9.89% | Upgrade
|
| Prepaid Expenses | 0.87 | 1.13 | 2.52 | 3.41 | 0.62 | 0.44 | Upgrade
|
| Other Current Assets | 13.3 | 3.48 | 2.62 | 8.14 | 7.81 | 7.28 | Upgrade
|
| Total Current Assets | 866.02 | 907.22 | 367.23 | 167.04 | 210.53 | 256.1 | Upgrade
|
| Property, Plant & Equipment | 0.89 | 1 | 1.13 | 1.42 | 0.03 | 0.32 | Upgrade
|
| Long-Term Deferred Charges | 0.03 | 0.06 | 0.11 | 0.04 | 0.08 | 0.05 | Upgrade
|
| Other Long-Term Assets | 0.05 | 0.05 | 0.03 | 0.03 | 0.03 | 0.03 | Upgrade
|
| Total Assets | 866.99 | 908.32 | 368.49 | 168.53 | 210.66 | 256.5 | Upgrade
|
| Accounts Payable | 7.7 | 9.81 | 7.51 | 8.53 | 1.44 | 3.99 | Upgrade
|
| Accrued Expenses | 11.37 | 17.11 | 11.3 | 13.11 | 7.31 | 7.81 | Upgrade
|
| Current Portion of Leases | 0.5 | 0.49 | 0.32 | 0.3 | 0.03 | 0.33 | Upgrade
|
| Total Current Liabilities | 19.57 | 27.41 | 19.14 | 21.95 | 8.78 | 12.13 | Upgrade
|
| Long-Term Leases | 0.5 | 0.63 | 0.94 | 1.26 | - | 0.03 | Upgrade
|
| Total Liabilities | 20.08 | 28.04 | 20.07 | 23.21 | 8.78 | 12.16 | Upgrade
|
| Common Stock | 0 | 0 | 0 | 0 | 0 | 0 | Upgrade
|
| Additional Paid-In Capital | 1,381 | 1,369 | 733.55 | 445.27 | 425.61 | 412.59 | Upgrade
|
| Retained Earnings | -533.54 | -487.91 | -377.94 | -292.05 | -223.18 | -168.19 | Upgrade
|
| Treasury Stock | - | - | -6.8 | -6.8 | - | - | Upgrade
|
| Comprehensive Income & Other | -0.22 | -0.79 | -0.39 | -1.1 | -0.55 | -0.05 | Upgrade
|
| Shareholders' Equity | 846.92 | 880.28 | 348.42 | 145.32 | 201.88 | 244.34 | Upgrade
|
| Total Liabilities & Equity | 866.99 | 908.32 | 368.49 | 168.53 | 210.66 | 256.5 | Upgrade
|
| Total Debt | 1 | 1.12 | 1.26 | 1.56 | 0.03 | 0.36 | Upgrade
|
| Net Cash (Debt) | 850.86 | 901.49 | 360.82 | 153.92 | 202.07 | 248.03 | Upgrade
|
| Net Cash Growth | -11.53% | 149.85% | 134.42% | -23.83% | -18.53% | -9.80% | Upgrade
|
| Net Cash Per Share | 7.65 | 8.27 | 3.82 | 2.00 | 2.62 | 3.42 | Upgrade
|
| Filing Date Shares Outstanding | 111.57 | 112.25 | 100.49 | 78.42 | 78.36 | 74.13 | Upgrade
|
| Total Common Shares Outstanding | 111.57 | 111.57 | 100.11 | 78.26 | 78.25 | 73.22 | Upgrade
|
| Working Capital | 846.45 | 879.8 | 348.09 | 145.09 | 201.75 | 243.98 | Upgrade
|
| Book Value Per Share | 7.59 | 7.89 | 3.48 | 1.86 | 2.58 | 3.34 | Upgrade
|
| Tangible Book Value | 846.92 | 880.28 | 348.42 | 145.32 | 201.88 | 244.34 | Upgrade
|
| Tangible Book Value Per Share | 7.59 | 7.89 | 3.48 | 1.86 | 2.58 | 3.34 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.